Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization

Agathe Dubuisson1,2,3, Célec Favreau1,3, Eric Fourmaux2, Sabrina Lareure2, Rafael Rodrigues-Saraiva1,3, Catherine Pellat-Deceunynck4, Said El Alaoui2 and Olivier Micheau1,2,3

Abstract

Development of therapeutic antibodies in oncology has attracted much interest in the past decades. More than 30 of them have been approved and are being used to treat patients suffering from cancer. Despite encouraging results, and albeit most clinical trials aiming at evaluating monoclonal antibodies directed against TRAIL agonist receptors have been discontinued, DR4 or DR5 remain interesting targets, since these receptors are overexpressed by tumour cells and are able to trigger their death. In an effort to develop novel and specific anti-DR4 and anti-DR5 antibodies with improved properties, we used genetic immunization to express native proteins in vivo. Injection of DR4 and DR5 cDNA into the tail veins of mice elicited significant humoral anti-DR4 and anti-DR5 responses and fusions of the corresponding spleens resulted in numerous hybridomas secreting antibodies that could specifically recognize DR4 or DR5 in their native forms. All antibodies bound specifically to their targets with a very high affinity, from picomolar to nanomolar range. Among the 21 anti-DR4 and anti-DR5 monoclonal antibodies that we have produced and purified, two displayed proapoptotic properties alone, five induced apoptosis after cross-linking, four were found to potentiate TRAIL-induced apoptosis and three displayed antiapoptotic potential. The most potent anti-DR4 antibody, C#16, was assessed in vivo and found, alone, to inhibit tumour growth in animal models. This is the first demonstration that DNA-based immunization method can be used to generate novel monoclonal antibodies targeting receptors of the TNF superfamily that may constitute new therapeutic agents.

Introduction

TRAIL (tumour necrosis factor-related apoptosis inducing ligand) agonist receptors, DR4 and DR5, have for more than two decades been considered as potential targets for cancer therapy owing to their ability to trigger selective apoptosis in tumour cells while sparing normal cells1,2. Clinical evaluations of TRAIL, the natural ligand of DR4 and DR5, or anti-DR4/DR5 antibodies, alone or combined with chemotherapy, have, however, been discontinued owing to lack of efficacy3. The sole exceptions, to date, include the clinical studies of the novel TRAIL recombinant protein developed by Sunbio Biotech4. The recombinant protein Circularly Permuted TRAIL has been found to increase objective response in patients suffering from multiple myeloma, alone or combined with thalidomide5,6. Engagement of apoptosis by TRAIL agonist receptors mostly relies on the ability of the ligand or agonist antibodies to induce receptor aggregation. Accordingly, increasing TRAIL agonist valency enhances their proapoptotic activity up to 100-fold7–9. Mechanistically, the binding of TRAIL or agonist antibodies to DR4 and DR5 allows recruitment of the adaptor protein FADD, which in turn enables the binding of the initiator cysteine protease, caspase-8,
within a supramolecular scaffold coined DISC for Death Inducing Signalling Complex\textsuperscript{10}. Within this scaffold, the zymogen caspase gets activated by proximity\textsuperscript{11} and released to the cytosol, where it can cleave other proteases such as caspase-3, another cysteine protease responsible for the execution phase of the apoptotic machinery. To date, antibodies assessed in the clinic have mostly focussed on DR5, with only one anti-DR4 evaluated in phase I/II\textsuperscript{4}. Keeping in mind that DR4 prevails over DR5 in cell death\textsuperscript{13,14}, development of antibodies targeting these receptors still holds interest in oncology.

Development of therapeutic antibodies by immunization is today an optimized and well-controlled process. Conventional immunization is mostly based on recombinant proteins or peptides\textsuperscript{15–17}. However, not all targets can be reproduced recombinantly. Their highly hydrophobic nature or conformational and topological complexity can make them difficult to produce\textsuperscript{18}. In particular, generation of antibodies directed against multiple transmembrane proteins has proved to be difficult. Moreover, protein folding can be altered by the production and purification processes or due to the lack of their transmembrane domain. The difficulty to generate certain posttranslational modifications makes the endogenous and native conformations of the immunogenic protein and its native epitopes hard to reproduce in vitro\textsuperscript{19,20}. To overcome these problems, a new approach of immunization was developed in the early 90s, coined genetic immunization\textsuperscript{21,22}. Originally developed as a vaccination method\textsuperscript{23}, DNA immunization has demonstrated its ability to induce significant cellular and humoral response\textsuperscript{24}. DNA immunization was found to be more effective than protein immunization in activating B cells in the germinal centre. It has also presented advantages for the production of monoclonal antibodies (mAbs)\textsuperscript{25}. We describe here the characterization of several monoclonal anti-DR4 and -DR5 antibodies developed by this approach displaying proapoptotic activity or able to synergize with TRAIL.

Materials and methods
Ligand, chemicals and antibodies

His-tagged human TRAIL was produced and used as described previously\textsuperscript{26}. The anti-DR4 (clone wB-K32) and anti-DR5 (clone B-L27) antibodies, from Diaclone (Besançon, France), were used for flow cytometry\textsuperscript{27}. Alexa-488-conjugated-goat anti-mouse secondary antibody was from Molecular Probes (Life Technologies, Saint Aubin, France). For apoptosis measurement, Annexin V (No. 556422) and 7-aminoactinomycin D (7AAD; No. 559925) were from BD Biosciences (Le Pont de Claix, France). For western blot analysis, anti-DR4 (clone AB16955) antibody was purchased from Chemicon (Millipore, Molsheim, France). Antibodies against caspase-3 (clone MF393), caspase-8 (clone 5F7) and anti-caspase-9 (clone 5B4) were from Medical & Biological Laboratories (Clinisciences, Montrouge, France). The anti-cleaved poly ADP-ribose polymerase-1 (PARP-1; clone D64-E10) was from Cell Signaling Technology (Ozyme, Saint Quentin, France). Antibodies against PARP-1 (clone H-300), GAPDH (clone 0411) and HSC70 (clone B-6) were from Santa Cruz Biotechnology (CliniSciences). Horseradish peroxidase (HRP)-conjugated anti-rabbit was from Jackson ImmunoResearch (Interchim, Montluçon, France). HRP-conjugated anti-mouse immunoglobulin heavy chain+light chain (IgG (H+L)) secondary antibody was from CovalAb (Villeurbanne, France). HRP-conjugated anti-mouse IgG1-, Ig2a- and Ig2b-specific antibodies were obtained from Southern Biotech (Clinisciences). The caspase inhibitor, Q-VD-Oph, was from Selleck Chemicals (Munich, Germany).

Puromycin was purchased from InvivoGen (Toulouse, France); IdeZ enzyme from Promega (Charbonnieres, France). Protein A high-performance affinity columns (cat# 17-0402-01) and NP PROTEIN A SEPH 4 FF (cat# 17-5280-02) were from GE Healthcare (Dutscher, Brumath, France). Hypoxanthine–aminopterin–thymidine (HAT; cat# H0262) and polyethyl glycol (PEG; cat# P2906) were from Sigma (St Quentin Fallavier, France). H.hybridoma cloning supplement (HCS; cat# sc-224479) from Santa Cruz.

Animals

Mice used for these studies were maintained in a specific pathogen-free zone in accredited animal facility. All experiments were performed in compliance with the Committee of Ethics of Grand Campus de Dijon (C2EA grand campus Dijon) no. 105 – C2EA105. Eight-week-old female Balb/c mice (Charles Rivers France, St Aubin-les-Elbeuf) were used for the immunization protocol, and 8-week-old female Balb/c nude mice (Charles Rivers) were used for the tumour growth evaluation following antibody injections.

Plasmid constructs

Plasmids encoding soluble recombinant versions of DR4 or DR5 fused to the constant fraction of human gamma-immunoglobulin, i.e. DR4 (DR4-Fc) or DR5 (DR5-Fc), and conferring resistance to puromycin were constructed by PCR following In-Fusion manufacturer’s instructions (In-Fusion HD cloning, Takara, Clontech), using the following primers OR435 5’-GGG-AAA-CGA-TCC-TCA-TCC-TGT-CTC-TTG-ATC-GATC-3’; OR436 5’-TGG-CGA-TAA-GCC-AGT-AAG-CAG-TGG-GTT-CT C-TAG-3’; OR437 5’-ACT-GGC-TTA-TGG-AA-AT A-ATA-CGA-CTC-CTC-ATA-GGG-AGA-CCC-AAG-3’;
OR438  5’-GTG-CCT-GAG-CGG-GAC-TCT-GGG-GT
T-3’; OR439 5’-TGA-GGA-TGG-TTT-CGC-CAT-GA
C-CGA-GTA-CAA-GCC-C-3’ and OR446 5’-GTC-CC
G-CTC-AGG-CAC-CGG-GCT-TGC-3’. Briefly, the neo-
mycin cassette of the pCR3-neo-hDR4-Fc and pCR3-neo-
hDR5-Fc expression vectors (generous gift from Dr Pascal
Schneider, Epalinges, Switzerland) was replaced by puo-
mycin by assembling PCR fragments obtained using
OR435/OR436 and OR439/OR446 from each vector to the
cDNA encoding resistance to puromycin generated by PCR
amplification from OM181, a retroviral vector derived
from pMSCV-Puro, resulting in the pCR3-Puro-hDR4-Fc
(OM1450) and pCR3-Puro-hDR5-Fc (OM1449) constructs.

The pCR3-based plasmids encoding DR4 or DR5 full
length (pCR3-DR4 and pCR3-DR5) under the control of the
CMV promoter were kindly given by Dr Pascal
Schneider. The CAG promoter-derivative plasmid encoding
WPRE and GM-CSF full length, pCAGGS-GM-
CSF (OM1463), was obtained by PCR, using the pCAGGS
plasmid described by Niwa et al.28, a WPRE containing
vector synthesized from Genscript (GenEZ ORF clone
OMU22984D, OM1459) and the following primers were
formed using the Lipofectamine 3000, according to the
provider’s recommendations (Thermo Fisher Scientific,
Courtaboeuf, France). Transfected cells were grown in
culture dish at 60% confluence. When the con-
fluence reached

**Recombinant protein production**

DR4-Fc and DR5-Fc expressing stable cell lines (293T-
DR4-Fc and 293T-DR5-Fc, respectively) were obtained by
transfections of the pCR3-DRs-Fc plasmids (OM1449 or
OM1450) into 293T cells cultured in a 10-cm tissue
culture dish at 60% confluence. Transfections were
performed using the Lipofectamine 3000, according to the
provider’s recommendations (Thermo Fisher Scientific,
Courtaboeuf, France). Transfected cells were grown in
culture medium for 24 h, then treated with DMEM supple-
mplemented with 2.5 µg/mL of Puromycin. After selection,
293T-DR4-Fc and 293T-DR5-Fc cells were cultured in
T175-mm² culture flasks. When the culture reached
80%, the medium was changed to a synthetic medium,
OptiMEM Glutamax (Thermo Fisher Scientific), to boost
protein production. After 5 days of incubation, the
supernatant was harvested and proteins were purified as
follows. Supernatant containing recombinant DRs-Fc
protein was passed onto a high-performance protein-A
column, washed twice with cold phosphate-buffered sal-
sine (PBS) 1x, then recombinant proteins were eluted with
a 0.1 M citrate NaOH pH 2.5 solution, buffered with a
1 M Tris-HCl pH 9. The resulting pH 7 neutral solution
was sterilized using pyrogenic 0.2-micron filtration
membranes and concentrated with Centriforc (Millipore)
to reach the concentration of 1 or 2 mg/mL. Cleaved
receptors, devoid of Fc, cDR4 and cDR5 recombinant
proteins were obtained using IdeZ enzyme following the
manufacturer’s recommendations.

**DNA immunization protocol**

Balb/c mice were immunized with either 50 µg pCR3-
DR4 or 50 µg pCAGGS-DR5 and 2.5 µg pCAGGS-GMCSF
were performed (Macherey-Nagel, NucleoBond® Xtra
Maxi EF).
diluted in saline buffer via hydrodynamic tail vein (HTV) injection as previously described\(^3\). DR4 DNA injections were performed once a week during 4 weeks, whereas DR5 DNA injections were performed every 14 days during 8 weeks. To follow-up the production of antibodies, blood samples were taken after the third HTV immunization and sera were tested by enzyme-linked immunosorbent assay (ELISA).

**Detection of human anti-DR antibody titration by ELISA**

Determination of anti-DR4 or anti-DR5 antibody titres from mice sera, hybridoma supernatants or purified antibodies was assessed by ELISA. Sera from Balb/c mice were taken during immunization, hybridoma supernatants and purified antibodies were tested during mAb development. They were screened on recombinant cleaved soluble receptors, cDR4 and cDR5, respectively. ELISA have been performed as follows. Recombinant cDR4 and cDR5 were coated to 96-well EIA/RIA flat bottom microtitre plates (Corning, Costar 3590, Thermo Fisher Scientific). Hybridoma supernatant samples were diluted by half; sera and purified antibodies were serially diluted by half. After binding for 1 h at 37 °C on a rotating plate and incubation with the secondary antibody, reactivity was measured at 450 nm using a microplate reader (Labsystems Multiskan Ascent, Bradenton, USA). Samples were considered positive when the optical density was >0.3 for supernatant of hybridomas. Titres of purified antibodies were evaluated as the highest dilution (in ng/mL) where optical density is ≥1.

**Production of mAbs**

Fusions were performed from the most responsive mice. Briefly, spleens were harvested and splenocytes were extracted then fused to Sp2/0Ag mouse myeloma cells using PEG\(^3\). In all, 2 × 10\(^5\) cells/mL were then distributed into 96-well plate with medium containing 20% FCS, HAT and HCS. Three weeks post-fusion, supernatants were screened for antibody production by ELISA. All antibody-secreting hybridomas demonstrating significant positivity by flow cytometry underwent two rounds of sub-cloning. Selected sub-clones were then expanded for large-scale production. Twenty-one clonal hybridoma supernatants were then purified by Protein-A affinity chromatography.

**Flow cytometry**

Determination of selectivity was performed by flow cytometry using HCT116 cells or isogenic cell lines originating from MDA-MB-231 cells, expressing either DR4 or DR5 or none (DKO) of these receptors\(^12\). Flow cytometric analyses were performed using either hybridoma supernatants or purified antibodies. Hybridoma supernatants were screened on parental HCT116 and HCT116-DKO cells for DR4 clones and on MDA-MB-231 DKO and isogenic MDA-MB-231-DKO-DR5\(^{13}\) cells for DR5 clones. Purified antibodies were screened on MDA-MB-231-DKO, MDA-MB-231-DKO-DR4\(^{13}\) and MDA-MB-231-DKO-DR5\(^{13}\) cells. Cells were collected from culture flasks, washed with ice-cold PBS (Sigma) and dispatched in FACS tubes at 10\(^5\) cells per condition. Hybridoma supernatants were screened neat, and purified antibodies were diluted 1/100th in PBS containing 3% FCS. Samples were added to cells and incubated at 4 °C for 30–60 min. Tubes were then centrifuged and washed with PBS. Cells were then incubated at 4 °C for 30–40 min with AF488-conjugated goat anti-mouse IgG (H+L) diluted 1/200th in PBS containing 3% FCS and washed prior analysis by flow cytometry using a FACS-CANTO flow cytometer (BD Biosciences). Analysis were next performed using the FlowJo software.

**Affinity determination**

The affinity and cross-reactivity were determined using an Octet Red system and anti-human IgG quantification (AHQ) biosensors (FortéBIO, St Germain en Laye, France). All reagents were prepared in binding buffer (TRIS-NaOH 0.1 M, pH 7.4). Recombinant DR4-Fc and DR5-Fc were prepared at 5 µg/mL in binding buffer, fixed to the biosensor and then put in contact with the antibody of interest. The assay plate was agitated at 1000 rpm at 30 °C. Two columns (8 each) of biosensors were prehydrated in binding buffer for 10 min. Anti-hlgG biosensors were baselined for 180 s before and after loading of recombinant DR4-Fc or DR5-Fc (800 s). The binding kinetics were measured by dipping loaded biosensors (120 s) in varying concentrations of mAbs (from 500 nM to 15 nM). Next, dissociation was recorded for an additional 600 s. Interactions were monitored during association and dissociation period. Biosensors were then regenerated with three cycles of 5 s in regeneration buffer (citrate-NaOH pH 2.5) followed by neutralization in binding buffer. The data were fit to a 1:1 binding stoichiometric model. All octet experiments were designed and analysed with the FortéBio data acquisition software (7.1) and Data Analysis Software version 7.1.0.36 with Savitsky–Golay filtering to reduce noise. The data were adjusted with the version 5 of the GraphPad software.

**Viability and apoptosis assays**

Effects of mAbs of interest were measured on HCT116, MDA-MB-231 and BL2 cells. Viability was determined using methylene blue assay as described earlier\(^3\). HCT116 or MDA-MB-231 (5 × 10\(^5\)/mL cells) were plated into 96-well plates and incubated overnight at 37 °C with cascade dilutions of treatments (mAbs alone, TRAIL alone and an isoconcentrations of combined mAbs and TRAIL) starting from 10 µg/mL. Supernatants containing
or not dead cells were discarded, wells were washed with PBS and remaining adherent cells were fixed with methanol. After a 15-min incubation, methanol was discarded, dried and cells were stained using methylene blue for 15 min at room temperature. Stained cells were extensively washed, and plates were dried for 2 h at 37 °C. Subsequently, methylene blue was eluted with HCl 0.1 M and absorbance was measured at 630 nm using the Asys UVM 340 microplate reader from Biochrom (Cambridge, UK). Percentage of cell viability vs. medium was calculated relative to non-stimulated cells, corresponding to 100% survival.

Apoptosis induced by mAbs combined or not to TRAIL was quantified by allophtocyanin Annexin V (fluorescein isothiocyanate) and 7AAD staining, according to the manufacturer’s instructions (BD Biosciences), and analysed by flow cytometry (FACS LSRII). BL2 cells were plated at 2 × 10^5 cells/mL in 24-well plates and incubated with mAbs at 10 µg/mL alone or in combination with 1 µg/mL TRAIL for 20 h. Prior treatments, corresponding wells were treated with 10 µM of Q-VD-Oph (Selleckchem), a caspase inhibitor, for 30 min at 37 °C. MDA-MB-231 cells were plated at 1 × 10^6 cells/mL in T25-mm² flasks and incubated with mAbs at 5 µg/mL alone or combined to 1 µg/mL TRAIL for 8 h. The inhibitory apoptosis potential of C#21 and C#23 antibodies was assessed by flow cytometry on HCT116-DKO-DR5^−/− as described above. To test the activity of C#16, in human cancer cell lines, BL2, H1703, HCT116 and MDA-MB-231, cells were plated at 2 × 10^5 cells/mL in 24-well plates and incubated with a dilution of C#16 ranging from 10 to 0.3 µg/mL for 24 h. All the above-mentioned experiments were repeated at least three times.

**Immunoblot analyses**

Dot blots were performed using purified recombinant DR4 and DR5. Soluble receptors, denatured or not in the presence of 1 M dithiothreitol (DTT) for 5 min at 95 °C, were deposited onto nitrocellulose membranes and dried for 15 min. Membranes were then blocked in PBS-T (PBS, 0.5% Tween 20) containing 5% non-fat dry milk (PBS-TM) for 1 h and incubated with anti-DR4 and anti-DR5 antibodies diluted 1/1000th overnight at 4 °C. The next day, the membranes were washed three times with PBS-T and the binding was detected with an anti-mouse IgG (H + L)–HRP antibody.

For immunoblots, BL2, H1703, HCT116 or MDA-MB-231 cells were put at 1 × 10^6 cells/mL in T25-mm² flasks and incubated with mAbs at 5 or 1 µg/mL alone or in combination with 1 µg/mL of TRAIL for a final volume of 10 mL. Supernatants and cells were collected 8 h later and cell lysates were prepared using NP40 lysis buffer containing 1% NP40, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and a proteinase inhibitor cocktail (Roche, Meylan, France). Cell extracts were run on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Proteins were transferred to nitrocellulose membrane (Bio-Rad) by liquid electro-blotting using the criterion blotter apparatus (Bio-Rad). Membranes were next saturated using PBS-TM for 1 h and incubated with primary antibodies in PBS-TM overnight at 4 °C on a rotating machine. Washed three times with PBS-T before incubation for 1 h with HRP-conjugated secondary antibodies diluted 1/10,000th in PBS-TM, membranes were then washed three times with PBS-T and immunoreactivity detected using the chemiluminescence detection kit Western BrightQuantum Kit from Advansta (Menlo Park, CA, USA).

**In vivo assays**

Female athymic nude mice (Balb/c nu/nu) aged between 7 and 8 weeks were injected subcutaneously in the lower right flank with 1 × 10^7 BL2 cells mixed with Matrigel (Corning). After randomization, 5–6 mice were injected i.p. with C#16 (10 mg/kg) or vehicle control (PBS). For pre-established xenograft tumour model, when tumour reached approximately 100 mm³, mice were injected with C#16 (10 mg/kg) or vehicle control (PBS) on days 16, 20, 24, 28 and 32 post BL2 inoculation. For de novo model, mice were injected with C#16 (10 mg/kg) or vehicle control (PBS) on days 4, 8, 12, 16, 20 and 24 post BL2 inoculation. For all groups, tumour size was measured on two axes with digital callipers every 2 days. The values were transformed into tumour volumes using the following formula: tumour volume (mm³) = (Length × Width²)/2. Mice were euthanized when the tumour reached 1500 mm³ or at the end of the experiment (day 34).

**Statistical analysis**

Unless specified, statistical analyses were conducted with the GraphPad software by comparing two group by paired t test and all the groups with each other using analysis of variance and Bonferroni’s post-test. For all tests, only data resulting in p values <0.05 were regarded as statistically significant.

**Results**

**Generation of anti-DR4 and -DR5 antibodies by DNA immunization**

DNA immunizations were performed using a proprietary CovalAb protocol, based on previous studies. Mice were immunized with DR4 or DR5 plasmids and immune reactivity was evaluated by ELISA on mouse serum. When a good titre was obtained, spleens of selected mice were fused to obtain hybridoma cells. After 3 weeks of culture, the supernatants from the resulting hybridomas were screened by ELISA (Figure S1A). Out of this screening, several antibody-secreting clones were analysed by dot
blot and FACS analysis to determine their potential ability to bind to recombinant DR4 and/or DR5 or native receptors on parental HCT116 or isogenic MDA-MB-231 cells expressing solely DR5 as indicated. All antibodies targeting DR4 (Figure S1B) or DR5 (Figure S1C) exhibited positive signal for their corresponding targets. None of the above-described antibodies bound MDA-MB-231-DKO cells deficient for DR4 and DR5 (Figure S1C and not shown). Of these, a limited number of them was next chosen for antibody production and purification.

Characterization of purified anti-DR4 and anti-DR5 antibodies by ELISA, dot blot and flow cytometry

As demonstrated by ELISA, 19 hybridomas produced antibodies displaying good to excellent immune-reactivity with titres ranging from 4 to 80 ng/mL (Figure S2A). Dot blot analysis performed using recombinant cDR4 or cDR5, denatured or not with DTT, indicated that all antibodies generated by the DNA approach recognized specifically the native form of the protein target (Figure S2B). Consistent with this finding, analysis of their binding selectivity by flow cytometry, using MDA-MB-231-DKO, deficient for both receptors (grey histograms), as compared to isogenic cells reconstituted with either DR4 (MDA-MB-231-DKO-DR4rec, blue histograms) or DR5 (MDA-MB-231-DKO-DR5rec, red histograms), demonstrated that all these mAbs were highly specific for their corresponding targets, namely DR4 (Fig. 1a) or DR5 (Fig. 1b).

Analysis of the proapoptotic potential of DR4 and DR5 antibodies

Given that the antibodies recognize the native form of TRAIL agonist receptors, we next investigated whether some of them might display proapoptotic functions. To address this question, five anti-DR4 (clones C#1, C#2, C#5, C#11, C#16) and four anti-DR5 antibodies (clones C#21, C#22, C#23, C#24), were produced in larger quantities and evaluated, by methylene blue or Annexin V staining, for their ability to induce the loss of cell viability or apoptosis in a panel of human tumour cell lines sensitive or resistant to TRAIL-induced cell death. Remarkably, from this rather limited panel of antibodies, the mAb targeting DR4, C#16, and the anti-DR5, C#22, were both able to partially reduce, alone, the cell viability of the colorectal cancer cell line HCT116, in a dose-dependent manner (Fig. 2a). This finding is particularly remarkable for such a screen, as agonist mAbs developed, so far, against DR4 and DR5, with a few exceptions, often require cross-linking agents or sensitizing drugs such as the proteasome inhibitor bortezomib to unmask their proapoptotic potential. None of them, however, appeared to inhibit the cell viability of the TRAIL-resistant breast carcinoma triple-negative cell line MDA-MB-231, albeit, at the highest concentration, C#22 had a tendency to reduce the cell viability of these cells (Fig. 2a). Nonetheless, and consistent with the results obtained in HCT116 cells, C#16 and C#22 were, alone and without cross-linking nor enhancer, able to induce >75% and 35% apoptosis respectively, in BL2 cells (Fig. 2b). As expected, cell death-induced by these two antibodies in BL2 cells was inhibited by the pan-caspase inhibitor Q-VD-Oph (Fig. 2b). Since C#16 is the most potent antibody identified in our screen, its apoptosis-inducing properties were monitored by Annexin V staining in a larger panel of cell lines. Interestingly, C#16 induced apoptosis in a dose-dependent manner not only

![Fig. 1 Cell surface receptor recognition of the produced anti-DR4 and anti-DR5 antibodies](image-url)

*Fig. 1 Cell surface receptor recognition of the produced anti-DR4 and anti-DR5 antibodies.* MDA-MB-231 DKO (grey curve) and MDA-MB-231 DKO reconstituted with either DR4 (MDA-MB-231-DKO-DR4rec, blue curve) or DR5 (MDA-MB-231-DKO-DR5rec, red curve) were stained with a anti-DR4 antibodies or b anti-DR5 antibodies. Primary antibodies were then detected using a AF488-conjugated mouse-specific IgG (H+L) secondary antibody and analysed by flow cytometry.
in HCT116, BL2 and the lung carcinoma H1703 cell lines but also, although to a lesser extent, in MDA-MB-231 cells (Fig. 2c). Consistent with these findings, the immunoblot analysis of caspase activation, caspase substrate cleavage or cleaved products, clearly demonstrated that C#16 through binding to DR4 is able to induce activation of the canonical extrinsic pathway (Fig. 2d). Likewise, disappearance of caspase-8 proform, as well as appearance of cleaved PARP products occurred in BL2, H1703 or HCT116 cells, as efficiently as cells stimulated with TRAIL (Fig. 2d). The anti-DR4 mAb C#1 was used, here, as a negative control, as even at the highest concentration, and contrary to C#16, C#1 was not able to induce the caspase cascade nor the cleavage of endpoint products such as PARP (Fig. 2d). Because C#16 was as efficient as Mapatumumab in inducing apoptosis in BL2 cells (Fig. 2e), its ability to inhibit tumour growth in vivo was assessed in nude mice. For this purpose, BL2 lymphoma cells mixed with Matrigel were implanted in the right flank of nude mice and xenografted animals were treated or not with 5–6 injections of C#16 at 10 mg/kg, every 4 days, either when the tumour reached approximately 100 mm³ or 4 days after tumour implantation and randomization. The effect of C#16 in pre-established BL2 tumours was significant, leading to 30% loss of tumour growth (Fig. 3a). When the antibody was injected 4 days after implantation, referred as the de novo experiment, the growth rate of BL2 cells was nearly four-fold lower in mice treated with C#16 (Fig. 3b).

Both DR4 and DR5 antibodies can synergize with TRAIL to induce apoptosis

The use of recombinant TRAIL or agonist antibodies targeting DR4 or DR5 alone to treat patients suffering from cancer is unlikely to translate to the clinic due to the poor ability of these agents to trigger sufficient apoptosis

Fig. 2 Apoptosis induced by anti-DR4 or -DR5 antibodies. a Viability of HCT-116 and MDA-MB-231 were determined using methylene blue, 16 h after treatment with increasing concentrations of anti-DR4 mAbs (C#1, C#2, C#5, C#11 and C#16) or anti-DR5 mAbs (C#21, C#22, C#23 and C#24). Values are means ± SD (n = 3). b BL2 cells were pre-incubated or not for 30 min at 37 °C with 10 µM of Q-VD-Oph prior stimulation for 20 h with 10 µg/mL of mAbs. Cells were next stained with Annexin V/7AAD and apoptosis was quantified by flow cytometry. c BL2, H1703, HCT116 and MDA-MB-231 cell lines were treated for 20 h with increasing concentrations of C#16, and apoptosis was quantified as above by flow cytometry. d BL2, H1703 and HCT116 cells were stimulated with 1 µg/mL His-TRAIL, 1 or 5 µg/mL of C#16 or 5 µg/mL C#1 for 8 h. Corresponding cell extracts were analysed by immunoblot. e BL2 cells were treated with increasing concentration of C#16 or Mapatumumab for 20 h, and apoptosis was quantified with Annexin V/7AAD staining by flow cytometry. All values are presented here as ±SD (n = 3). Significance was evaluated by analysis of variance tests. *p < 0.1, **p < 0.05, ***p < 0.01.
alone\textsuperscript{3,4}. However, increasing evidence suggest that it may be possible to combine TRAIL with antibodies targeting DR4 or DR5 to induce efficient apoptosis\textsuperscript{13,43–45}. Indeed, several of the antibodies that we have produced here in this study are able to enhance TRAIL-induced apoptosis. Accordingly, and as assessed by methylene blue, combined treatments in HCT116 and MDA-MB-231 cells lines with varying concentration of TRAIL and mAbs for 16 h revealed that 4 out of the 9 mAbs were able to synergize with TRAIL to inhibit the cell viability of these tumour cell lines (Fig. 4). More specifically, albeit not observed in the HCT116 cell line, two anti-DR4 (C#2 and C#11) and two anti-DR5 mAbs (C#22 and C#24) potentiated apoptosis induced by TRAIL in the resistant MDA-MB-231 cell line (Fig. 4b). Their synergistic potential was also clearly evidenced in the BL2 cell line, as monitored by Annexin V staining (Fig. 4c). On the other hand, our screen also identified three antibodies displaying inhibitory activity as well, namely C#5, C#21 and C#23. Likewise, although their inhibitory potential appeared modest based on the methylene blue assay in both HCT116 and MDA-MB-231 cells (Fig. 4a, b), and despite the fact that C#5 clearly displayed inhibitory potential in BL2 cells (Fig. 4c), in isogenic cell lines expressing either DR4 (Figure S3A) or DR5 (Fig. 4e), all three antibodies were found to be potent antagonists.

Characterization of the antibody-binding characteristics by biolayer interference (BLI)

In order to assess whether it may be possible to predict the biological activity of the main DR4 and DR5 antibodies solely based on their binding characteristics and define their affinity for their target, BLI was performed using DR4-Fc and DR5-Fc. The experimental curves were fitted using a 1:1 binding model to calculate the
association and dissociation constant rates and KD. All tested antibodies bound specifically to their corresponding receptor in a dose-dependent manner (Fig. 5a), and irrespective of whether they target DR4 or DR5, they displayed high affinity with KDs ranging from 20 pM to ~2 nM (Fig. 5b). Despite the fact that the affinity of some...
of the generated antibodies is stronger than TRAIL affinity for its cognate receptors, such as C#16 and C#24, only three of them exhibited potent inhibitory activity, suggesting that their binding likely involves distinct amino acids as compared to TRAIL. The anti-DR4 antibody C#5 and the anti-DR5 antibodies (clones C#21 and C#23), on the other hand, are likely to recognize amino acids required for TRAIL binding to DR4 or DR5, respectively.
since they all inhibited TRAIL-induced cell death (Fig. 4e and Supplementary Fig. 3A). The biological activity (agonist vs. enhancer) of the remaining antibodies could, however, not be predicted solely based on their binding constants. Likewise, albeit the agonist antibody C#16 displayed the lowest association and dissociation rates among all of the antibodies analysed in this study (Table 1), as illustrated with the on–off rate map (Fig. 5b), neither the association and dissociation constants nor overall affinity for a specific target could be associated with specific biological activity of DR4 or DR5 targeting antibodies. For instance, antibodies exhibiting TRAIL-induced apoptosis-enhancing activity (defined as enhancers mAbs) were all found to display distinct affinity for their target, ranging from 20 to 1740 pM (Table 1 and Fig. 5b). The biological properties of these antibodies are thus more likely due to specific recognition of the target in its native form.

Altogether, our work provides strong evidence that DNA immunization afforded generation of novel anti-DR4 and anti-DR5 antibodies recognizing native epitopes and displaying potential therapeutic effects.

**Discussion**

Given that cancer cells generally overexpress DR4 and DR5[46–49] and that, for a reason that still needs to be defined, signal transduction of apoptosis induced by these receptors appears to be fairly selective for tumour cells[1,50], targeting TRAIL agonist receptors remains an interesting strategy in current anticancer drug development[51]. Because these receptors represent easy to reach targets, a number of TRAIL derivatives, including recombinant TRAIL, peptidomimetics and agonistic mAbs targeting TRAIL receptors, have been generated and found to be able induce apoptosis in tumour cells in preclinical models[4,50]. However, whereas TRAIL or its derivatives, including anti-DR4 or anti-DR5 mAbs, have been reported to be safe in all animal models and well tolerated in humans, their clinical efficacy has, so far, proven to be rather limited[34,52].

Development of additional anti-DR4 and anti-DR5 mAbs exhibiting potent proapoptotic or TRAIL sensitizing activity potential could nonetheless be interesting to cure patients suffering from cancer. To achieve such an aim, we chose the hydrodynamic genetic immunization method that, to our knowledge, has never been used to generate anti-DR4 or anti-DR5 antibodies. This approach allowed us to generate monoclonal anti-DR4 and anti-DR5 antibodies displaying high affinity and specificity for their target, respectively, with high titres. Generated antibodies were not only almost all directed against the native conformational forms of DR4 or DR5 but also a high proportion of them displayed therapeutic potential, ranging from agonistic, TRAIL-enhancing to TRAIL-inhibiting activities.

Most TRAIL receptor-targeting agonist antibodies require cross-linking or immobilization of protein A or G[53,54] or immunoglobulin class switch[14] to unveil their proapoptotic potential[8]. Indeed, out of the 21 mAbs generated in this study, 5 anti-DR4 antibodies required cross-linking to trigger apoptosis (Figure S3B). Remarkably, however, the anti-DR4 C#16 or the anti-DR5 C#22 mAbs were able to induce cell death in HCT116 and BL2 in the absence of cross-linking. Unlike C#22 (not shown), but like Mapatumumab, albeit to a lesser extent, the proapoptotic activity of C#16 could still be increased after antibody-mediated cross-linking (Figure S3C). It should be stressed here that, while the cross-linking efficacy cannot be compared between our antibodies and Mapatumumab due to the use of species-specific cross-linking antibodies, this approach enabled us to unmask the proapoptotic potential of additional anti-DR4 mAbs including C#8, C#13 or C#14, further demonstrating that genetic immunization could be a method of choice to generate antibodies displaying therapeutic properties. These results are particularly remarkable given the limited number of hybridomas screened in our study.

### Table 1 Kinetic parameters of DR4 and DR5 mAbs towards DR4-Fc and DR5-Fc using BLI

| Agonists | C#16 | C#22 | C#2 | C#11 | C#24 |
|---------|------|------|-----|------|------|
| KD      | 3.8E−11 | 1.01E−10 | 1.74E−09 | 9.32E−10 | 2.05E−11 |
| Kon     | 1.9E+04 | 1E+05 | 2.5E+05 | 1.2E+05 | 1.7E+05 |
| Koff    | 7.3E−07 | 1.2E−06 | 4.4E−04 | 2.3E−06 | 3.5E−06 |
| X2      | 0.035 | 0.507 | 1.12 | 0.629 | 0.204 |
| R2      | 0.99997 | 0.99934 | 0.99216 | 0.99644 | 0.99903 |

| Antagonists | C#5 | C#21 | C#23 |
|------------|-----|------|------|
| KD         | 1.3E−10 | 2.3E−11 | 1.18E−10 |
| Kon        | 2.4E+05 | 1.3E+05 | 4.1E+05 |
| Koff       | 2.2E−04 | 3E−06 | 4.8E−05 |
| X2         | 0.637 | 0.116 | 0.223 |
| R2         | 0.99872 | 0.99928 | 0.99896 |

Equilibrium binding constants (KD) and association (kon) and dissociation (koff) rates were determined using biolayer interferometry (BLI) using 1:1 binding kinetics. Bindings of agonistic antibodies (C#16 and C#22), enhancers antibodies (C#2, C#11, C#22 and C#24) and antagonists (C#5, C#21 and C#23) to soluble recombinant versions of DR4 (DR4-Fc) or DR5 (DR5-Fc) fused to the constant fraction of human gamma-immunoglobulin were evaluated.

Dubuisson et al. *Cell Death Disease* (2019) 10:101
In the breast carcinoma cell line MDA-MB-231, however, the agonistic antibodies C#16 and C#22 were, alone, less efficient, owing to the fact that this cell line is naturally resistant to TRAIL-induced apoptosis due to high expression levels of the caspase-8 inhibitor cFLIP\(^{34}\). It should be added here that Mapatumumab, the only anti-DR4 assessed in the clinic, albeit as efficient as C#16 in inducing apoptosis in the BL2 cells, was also found previously to be poorly efficient in triggering apoptosis in MDA-MB-231 cells\(^{12}\).

However, and consistent with recent findings highlighting the ability of anti-DR4 and anti-DR5 antibodies to increase TRAIL-apoptosis signalling\(^{13,14,43}\), the anti-DR5 C#22 mAb was found to be able to enhance apoptosis induced by TRAIL in the resistant MDA-MB-231 cell line\(^{34}\). Importantly, besides C#22, another anti-DR5 antibody C#24, as well as two anti-DR4 antibodies, C#2 and C#11, were also found to be effective in enhancing apoptosis, both in the sensitive BL2 and the resistant MDA-MB-231 cells, when combined with TRAIL.

While it will be required to determine how these antibodies cooperate with TRAIL to increase apoptosis, the synergistic potential appears to be strictly related to the targeted receptor. Likewise, and as demonstrated here using isogenic cells expressing either DR4 or DR5\(^{12}\), even in the absence of the non-targeted receptor, combined treatments elicited stronger apoptosis than the addition of the single agents (Figure S3D).

All of the produced anti-DR4 and anti-DR5 antibodies bound to DR4 or DR5, respectively, and recognized their target in a conformational manner. Consistent with a recent study showing that the antitumour effect of DR4 agonist antibodies was not correlated with affinity, per se, but with epitope recognition\(^{14}\), the kinetic parameters of the different antibodies produced and analysed in our study were not predictive of their biological properties, suggesting that they might recognize different epitopes. Henceforth, while all our antibodies bound their target with high affinity, ranging from 20 pM to 2 nM, and albeit their association constants were fairly similar, with the exception of C#16, their dissociation characteristics differed substantially from \(7 \times 10^{-7}\) to \(4 \times 10^{-4}\) (s\(^{-1}\)). Whereas clone C#16 bound more slowly to its target, its overall affinity was high due to its low dissociation rate. On the other hand, DR4 enhancers (C#2 and C#11) both associated and dissociated very rapidly to and from their target while displaying a 100-fold lower affinity as compared to C#16, respectively. On the other hand, the kinetic parameters of the DR5 enhancers, C#24 and C#22, were clearly dissimilar. With a lower association constant rate as well as a lower dissociation rate, these enhancers displayed a 10–100-fold increase in affinity as compared to DR4 enhancers. Although it remains to be determined whether C#2 and C#11 may be able to bind to the same epitope, due to their affinity constant, C#24 and C#22 are unlikely to share the same epitope since C#22, contrary to C#24, displays both agonistic and synergistic properties. Taken together, these results substantiate the finding that TRAIL-mediated cell death can significantly be enhanced both by anti-DR4 and -DR5 mAbs.

Humanization and/or engineering optimization of the best leads will be required before considering these novel murine anti-DR4 and -DR5 antibodies for cancer therapy, including clone C#16. In particular, after humanization it will be important to determine whether the antitumour growth effects found in our study with this clone is solely mediated through its ability to trigger apoptosis through DR4 or whether its antitumour potential may also involve, at least partially, antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent cytotoxicity. In line with ADCC, several of the anti-DR4 or -DR5 antibodies raised here, irrespective of their ability to trigger apoptosis in the absence of cross-linking or combined with TRAIL, could potentially be of interest to deliver toxic agents to the tumour site.

**Conclusion**

Genetic immunization, unlike conventional approaches, is more likely to preserve not only the shape of the protein of interest but also their posttranslational modifications, allowing not only the generation of antibodies recognizing hard-to-produce transmembrane proteins but also antibodies displaying pharmacological properties. To our knowledge, this is the first time that genetic immunization has been used to generate antibodies against death receptors. Anti-DR4 and anti-DR5 mAbs generated using this DNA approach, as demonstrated here not only displayed, as expected, high affinity to their native targets, but remarkably, among the limited number of purified clones, almost 12 out of 21 displayed pharmacological properties. Beyond TRAIL, this proof of concept clearly opens novel opportunities for the use of genetic immunization to generate potential therapeutic antibodies.

**Acknowledgements**

OM is supported by grants from the ANR (Agence Nationale de la Recherche) program “Investissements d’Avenir” Labex LipStIC (ANR-11-LABX-0021-01), ANR grants (07-PCV-0031 and SphingoDR), the Conseil Regional de Bourgogne, COFECUB/CAMPUS FRANCE (Mé 888-17), the European commission FEDER (Fonds Européen de Développement Régional, BG0004892) and RISE (DISCOVER, 777995) and the foundation ARC (Association pour la Recherche sur le Cancer). A.D. was supported by a grant from the FEDER (BG0004892).

**Author details**

1. Université Bourgogne Franche-Comté, INSERM, UMR1231, F-21079 Dijon, France. 2. Research Department, CovalAb, 11 Avenue Albert Einstein, 69100 Villeurbanne, Lyon, France. 3. INSERM, UMR1231, « Équipe labellisée Ligue contre le Cancer » and Laboratoire d’Excellence LipStIC, F-21079 Dijon, France. 4. CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France.
10. Bodmer, J. L. et al. TRAIL receptor-2 signals apoptosis through FADD and DIABLO.
11. Muñoz, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S. & Dixit, V. M. A novel adenovirus-encoded suicide gene induces apoptosis in cervical carcinoma HeLa cells through AKT. *Plos ONE* **6**, e19679 (2011).
12. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**, 193–199 (1991).
13. Dufour, F. et al. *Nglycosylation of mouse TRAIL-R1 and human TRAIL-R1 with *N* acetylglucosaminyl transferases TRAIL-induced death. *Cell Death Differ.* **24**, 500–510 (2017).
14. Dimanche-Boitrel, M. T. et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. *Int. J. Cancer* **50**, 677–682 (1992).
15. Gaffo, A., Hove, S. C., Miletic, C., Butcher, G. W. & Howard, J. C. Antibodies to major histocompatibility antigens produced by hybrid cell lines. *Nature* **266**, 550–552 (1977).
16. Hazen, M. et al. An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins. *Mabs* **6**, 95–107 (2014).
17. Toscano, F. et al. p33-mediated upregulation of DCIR is required for TRAIL-induced synergistic anti-tumour potential in colon cancer cells. *Oncoimmunology* **7**, e1131380 (2016).
18. Wolf, J. A. & Carmichael, C. O. Hypertension restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. *Cell Death Dis.* **6**, e1633 (2015).
19. Montz, A. et al. Chemotherapy overcomes TRAIL-R-mediated resistance at the DISC level. *Cell Death Differ.* **18**, 700–711 (2011).
20. Sung, E. S. et al. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. *Mol. Cancer Ther.* **8**, 2276–2285 (2009).
21. Marzilli, E. et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. *Clin. Cancer Res.* **11**, 3126–3135 (2005).
22. Kang, Z. et al. Drotetuzumab, a human antibody to death receptor 5, has potent antitumor activity against thalidomide-refractory multiple myeloma and MM1S xenografts. *Cell Death Differ.* **16**, 386–398 (2009).
23. Peichold, M. P. et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor D5 DNA. *Int. J. Cancer* **131**, 2562–2572 (2012).
24. Huert, H. A. et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. *Mabs* **6**, 1560–1570 (2014).
25. Nagane, M., Shimizu, S., Mori, E., Kataoka, S. & Shiokawa, Y. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. *Neuro Oncol.* **12**, 687–700 (2010).
26. Luster, T. A., Carroll, J. A., McCormick, K., Sun, D. & Humphreys, R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. *Mol. Cancer Ther.* **8**, 292–302 (2009).
27. Tuthill, M. H. et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergize to kill cancer cells. *Oncogene* **34**, 2138–2144 (2015).
28. Guo, L. et al. Identification of novel epitopes with agonistic activity for the development of tumor immunotherapy targeting TRAIL-R1. *J. Cancer* **8**, 2542–2553 (2017).
29. Ganten, T. M. et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. *J. Med. Mol. Biol.* **87**, 995–1007 (2009).

### References

1. French, L. E. & Tschopp, J. The TRAIL to selective tumor death. *Nat. Med.* **5**, 146–147 (1999).
2. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *Nat. Med.* **5**, 157–163 (1999).
3. Mucio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S. & Dixit, V. M. A novel adenovirus-encoded suicide gene induces apoptosis in cervical carcinoma HeLa cells through AKT. *Plos ONE* **6**, e19679 (2011).
4. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**, 193–199 (1991).
5. Dufour, F. et al. *Nglycosylation of mouse TRAIL-R1 and human TRAIL-R1 with *N* acetylglucosaminyl transferases TRAIL-induced death. *Cell Death Differ.* **24**, 500–510 (2017).
6. Dimanche-Boitrel, M. T. et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. *Int. J. Cancer* **50**, 677–682 (1992).
7. Gaffo, A., Hove, S. C., Miletic, C., Butcher, G. W. & Howard, J. C. Antibodies to major histocompatibility antigens produced by hybrid cell lines. *Nature* **266**, 550–552 (1977).
8. Hazen, M. et al. An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins. *Mabs* **6**, 95–107 (2014).
9. Toscano, F. et al. p33-mediated upregulation of DCIR is required for TRAIL-induced synergistic anti-tumour potential in colon cancer cells. *Oncoimmunology* **7**, e1131380 (2016).
10. Wolf, J. A. & Carmichael, C. O. Hypertension restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. *Cell Death Dis.* **6**, e1633 (2015).
11. Montz, A. et al. Chemotherapy overcomes TRAIL-R-mediated resistance at the DISC level. *Cell Death Differ.* **18**, 700–711 (2011).
12. Sung, E. S. et al. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. *Mol. Cancer Ther.* **8**, 2276–2285 (2009).
13. Marzilli, E. et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. *Clin. Cancer Res.* **11**, 3126–3135 (2005).
14. Kang, Z. et al. Drotetuzumab, a human antibody to death receptor 5, has potent antitumor activity against thalidomide-refractory multiple myeloma and MM1S xenografts. *Cell Death Differ.* **16**, 386–398 (2009).
15. Peichold, M. P. et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor D5 DNA. *Int. J. Cancer* **131**, 2562–2572 (2012).
16. Huert, H. A. et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. *Mabs* **6**, 1560–1570 (2014).
17. Nagane, M., Shimizu, S., Mori, E., Kataoka, S. & Shiokawa, Y. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. *Neuro Oncol.* **12**, 687–700 (2010).
18. Luster, T. A., Carroll, J. A., McCormick, K., Sun, D. & Humphreys, R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. *Mol. Cancer Ther.* **8**, 292–302 (2009).
19. Tuthill, M. H. et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergize to kill cancer cells. *Oncogene* **34**, 2138–2144 (2015).
20. Guo, L. et al. Identification of novel epitopes with agonistic activity for the development of tumor immunotherapy targeting TRAIL-R1. *J. Cancer* **8**, 2542–2553 (2017).
21. Ganten, T. M. et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. *J. Med. Mol. Biol.* **87**, 995–1007 (2009).
47. Macher-Goeppinger, S. et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 15, 650–659 (2009).

48. Min, Y. J. et al. Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk. Res. 28, 359–365 (2004).

49. Bavi, P. et al. Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol. Cancer 9, 203 (2010).

50. Ashkenazi, A., Holland, P. & Eckhardt, S. G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26, 3621–3630 (2008).

51. Wajant, H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 22, 1727–1741 (2015).

52. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999).

53. Kaplan-Leffko, P. J. et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol. Ther. 9, 618–631 (2010).

54. Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437–448 (2004).